葵花药业：产品“复方聚乙二醇（3350）电解质散”取得注册证

Group 1 - The core point of the article is that Kew Flower Pharmaceutical Co., Ltd. has received a drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Powder from the National Medical Products Administration [1] - Kew Flower Pharmaceutical's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 99.61% of total revenue, while other businesses contribute only 0.39% [1] - As of the report date, Kew Flower Pharmaceutical has a market capitalization of 8.8 billion yuan [1]